SCOTUS ruling on mifepristone could have lasting impact on FDA regulation: Experts

While experts and advocacy groups applauded the U.S. Supreme Court's decision to not restrict nationwide access to the abortion pill mifepristone, they warn access to medication abortion remains at risk -- as does the very foundation of the Food and Drug Administration's regulation of all medications.